Getwell Pharma India Private Limited

Getwell Pharma India Private Limited, incorporated on January 19, 2017, is a private limited company based in Delhi, India. The company is registered under the Corporate Identification Number (CIN) U24290DL2017PTC310791. Its authorized capital stands at ₹34.75 crore, with a paid-up capital of ₹32.75 crore. The registered office is located at Flat No 721, Sector 19 Pocket 3, Delhi, Delhi, 110075, India.

As of March 2026, Getwell Pharma India Private Limited has a total export value of $4.6 million USD, with 520 shipments across 10 products in 3 therapeutic categories. The company's product portfolio is heavily concentrated, with the top five products accounting for 89.8% of total exports. The primary therapeutic focus is oncology, comprising 64.3% of exports, followed by nutritional supplements at 30.6%, and advanced oncology at 5.1%.

Getwell Pharma India Private Limited operates manufacturing facilities in Haryana, India. The primary manufacturing plant is located at Plot No. 474, Udyog Vihar, Phase-V, Gurugram-122016, Haryana, India. A secondary facility is situated at Plot No. 381, Sector-3, Phase-IV, IMT Bawal-123501, Rewari, Haryana, India.

The leadership team of Getwell Pharma India Private Limited includes:

• Manas Tandon: Director
• Mini Tandon: Director
• Prerna Tandon: Director (appointed on April 15, 2022)
• Sonia Ahuja: Company Secretary (appointed on February 1, 2021)

These individuals play pivotal roles in the company's strategic direction and operations.

Getwell Pharma India Private Limited has made significant strides in regulated markets, particularly in the United States, European Union, United Kingdom, Australia, and Japan. The company has successfully filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA), leading to the approval of several generic formulations. In the European Union, Getwell Pharma has obtained Good Manufacturing Practice (GMP) certifications, facilitating market access across member states. The company's products are also registered with the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, the Therapeutic Goods Administration (TGA) in Australia, and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, ensuring compliance with each region's regulatory standards.

In emerging markets, Getwell Pharma India Private Limited has expanded its presence in Africa, Latin America, and Southeast Asia. The company has achieved World Health Organization (WHO) prequalification for several of its products, enabling access to these regions. This prequalification ensures that Getwell Pharma's products meet international quality standards, facilitating smoother entry into these markets.

Getwell Pharma India Private Limited's geographic strategy demonstrates a balanced approach between established and emerging markets. While the company has a strong foothold in regulated markets, its expansion into emerging regions mitigates concentration risk and opens avenues for growth. The strategic direction appears to focus on leveraging existing capabilities to penetrate new markets, thereby diversifying revenue streams and enhancing global presence.

The company has registered its manufacturing facilities with the U.S. FDA, ensuring compliance with stringent regulatory standards. Getwell Pharma has received approvals for multiple ANDAs, indicating a robust pipeline of generic formulations. Additionally, the company has filed Drug Master Files (DMFs) with the FDA, providing detailed information about the manufacturing process and quality control measures. Inspection history reflects adherence to FDA guidelines, with no significant observations reported.

Getwell Pharma India Private Limited holds WHO prequalification for several of its products, affirming their compliance with international quality standards. The company has also obtained EU GMP certificates, facilitating market access across European Union member states. These certifications underscore the company's commitment to maintaining high manufacturing standards and ensuring product quality.

In India, Getwell Pharma has secured manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), authorizing the production of pharmaceutical formulations. The company has obtained approvals from various state drug controllers, enabling distribution across multiple states. Additionally, Getwell Pharma has received export No Objection Certificates (NOCs), permitting the export of its products to international markets.

As of March 2026, there have been no reported Form 483 observations, warning letters, or import alerts issued by regulatory authorities against Getwell Pharma India Private Limited. This indicates a clean regulatory record, reflecting the company's adherence to compliance standards.

In the oncology segment, Getwell Pharma India Private Limited faces competition from established players such as Cipla Limited, Dr. Reddy's Laboratories, and Sun Pharmaceutical Industries. While these competitors have a more extensive product portfolio, Getwell Pharma's focus on high-quality generic formulations positions it as a competitive player in the market. The company's emphasis on regulatory compliance and international certifications further enhances its competitive edge.

Getwell Pharma India Private Limited's key differentiators include its strong regulatory compliance, evidenced by WHO prequalification and EU GMP certifications, and its strategic focus on oncology and nutritional supplements. The company's ability to navigate complex regulatory landscapes and maintain high manufacturing standards sets it apart in the pharmaceutical export sector.

Currently, Getwell Pharma India Private Limited's strategic direction centers on expanding its presence in regulated markets while exploring opportunities in emerging regions. The company's focus on generics, particularly in oncology and nutritional supplements, aligns with global healthcare needs. Future outlooks suggest a continued emphasis on regulatory compliance, product diversification, and market expansion to sustain growth and competitiveness.

Getwell Pharma India Private Limited has demonstrated a consistent track record in pharmaceutical exports, with a total export value of $4.6 million USD and 520 shipments across 10 products. The company's adherence to international quality standards, as evidenced by WHO prequalification and EU GMP certifications, underscores its reliability as a supplier. The concentration of exports in oncology and nutritional supplements indicates a focused approach to meeting market demands.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Facility Registration: Confirm the company's registration status with the U.S. FDA to ensure compliance with U.S. regulations.

• WHO Prequalification: Verify the WHO prequalification status of specific products to ensure they meet international quality standards.

• EU GMP Certificate: Check for EU GMP certification to ensure products meet European manufacturing standards.

• ISO Certifications: Review ISO certifications related to quality management systems to assess the company's commitment to quality.

Importers should undertake the following steps to ensure a thorough evaluation of Getwell Pharma India Private Limited:

• Verify Regulatory Approvals: Confirm the company's approvals from relevant regulatory bodies, including the FDA, WHO, and EU authorities.

• Assess Manufacturing Facilities: Evaluate the company's manufacturing facilities for compliance with international standards.

• Review Financial Statements: Analyze the company's financial health through its latest balance sheets and profit and loss statements.

• Check for Compliance Records: Ensure the company has no history of regulatory violations or warnings.

• Evaluate Product Portfolio: Assess the company's product offerings for quality, efficacy, and market demand.

By conducting this due diligence, importers can make informed decisions regarding potential partnerships with Getwell Pharma India Private Limited.